Cargando…

miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3

Tumor recurrence by obtaining chemoresistance is a major obstacle to treating ovarian cancer. By TargetScan database and a luciferase reporter assay, we identified miR-150 directly targets Notch3, which is a key oncogene in ovarian cancer. We, therefore, investigated the role of miR-150 in ovarian c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Hoen, Jeong, Ju-Yeon, Park, Ju-Yeon, Kim, Se-Wha, Heo, Jin Hyung, Kang, Haeyoun, Kim, Gwangil, An, Hee Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641169/ https://www.ncbi.nlm.nih.gov/pubmed/29069826 http://dx.doi.org/10.18632/oncotarget.20348

Ejemplares similares

miR-22-3p and miR-30e-5p Are Associated with Prognosis in Cervical Squamous Cell Carcinoma
por: Kwon, Ah-Young, et al.
Publicado: (2022)

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells
por: PARK, SAE HYUN, et al.
Publicado: (2013)

Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer
por: Huh, J H, et al.
Publicado: (2013)

Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients
por: Lee, Hye Jin, et al.
Publicado: (2017)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation
por: Hong, Soon-Seok, et al.
Publicado: (2016)

Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
por: Park, Sun-Ae, et al.
Publicado: (2022)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers
por: Jeong, Ju-yeon, et al.
Publicado: (2013)

Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma
por: Li, Xiao, et al.
Publicado: (2015)

Pharmacokinetic Alteration of Paclitaxel by Ferulic Acid Derivative
por: Lee, Jaeok, et al.
Publicado: (2019)

Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer
por: Feng, Lanlan, et al.
Publicado: (2020)

AFM-Detected Apoptotic Changes in Morphology and Biophysical Property Caused by Paclitaxel in Ishikawa and HeLa Cells
por: Kim, Kyung Sook, et al.
Publicado: (2012)

Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel
por: Kim, Soo Yeon, et al.
Publicado: (2011)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)

Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation-like Feature Associated with Bile Duct Adenoma
por: Kwon, Ah-Young, et al.
Publicado: (2015)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

miR-107 Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel
por: Ma, Changpo, et al.
Publicado: (2019)

LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1
por: Shi, Cong, et al.
Publicado: (2018)

Role of hsa-miR-105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer
por: Li, Mao, et al.
Publicado: (2021)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

Mortality after Use of Paclitaxel-Coated Balloons Correlates with Total Cumulative Dosage of Paclitaxel in Real-World Analysis
por: Heo, Seon-Hee, et al.
Publicado: (2021)

Coronary Artery Thrombosis Associated With Paclitaxel in Advanced Ovarian Cancer
por: Park, Sang-Ho, et al.
Publicado: (2009)

Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer
por: Kim, Youngji, et al.
Publicado: (2015)

In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses
por: Lee, Jeong Hoon, et al.
Publicado: (2021)

Clinical trials and progress with paclitaxel in ovarian cancer
por: Kumar, Sanjeev, et al.
Publicado: (2010)

miR-433 overexpression attenuates the spindle assembly checkpoint response to paclitaxel
por: Furlong, F, et al.
Publicado: (2010)

Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer
por: Wang, Wenrui, et al.
Publicado: (2017)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
por: Kim, Ki Hyung, et al.
Publicado: (2009)

Correlation of ALDH1 and Notch3 Expression: Clinical implication in Ovarian Carcinomas
por: Kim, Mi Joung, et al.
Publicado: (2017)

DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the β-Catenin-P-Glycoprotein Signaling Pathway
por: Nguyen, Que Thanh Thanh, et al.
Publicado: (2022)

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer
por: Kim, Joo-Eun, et al.
Publicado: (2017)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
por: Jeong, Yeong Gyu, et al.
Publicado: (2023)

Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
por: Liu, Jing Jing, et al.
Publicado: (2019)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
por: Borghese, Cinzia, et al.
Publicado: (2020)

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells
por: XIE, ZHONGBIN, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sf9o12mfbcuk5hrcb7ve21pqs6